Home › Glioblastoma
Glioblastoma clinical trials recruiting in the U.S.
157 studies for Glioblastoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY30 studies
- Boston, MA28 studies
- Houston, TX25 studies
- Los Angeles, CA23 studies
- Durham, NC20 studies
- San Francisco, CA17 studies
- Washington, DC15 studies
- Rochester, MN15 studies
- Chicago, IL15 studies
- Miami, FL14 studies
- Columbus, OH14 studies
- Jacksonville, FL13 studies
- Aurora, CO12 studies
- St. Louis, MO12 studies
- Atlanta, GA11 studies
- Cleveland, OH11 studies
- Salt Lake City, UT11 studies
- Baltimore, MD11 studies
- Philadelphia, PA11 studies
- Baldwin Park, CA10 studies
- Pittsburgh, PA9 studies
- Birmingham, AL9 studies
- Dallas, TX9 studies
- Nashville, TN9 studies
- Phoenix, AZ8 studies
- Winston-Salem, NC8 studies
- Seattle, WA8 studies
- San Antonio, TX8 studies
- San Diego, CA7 studies
- Edison, NJ7 studies
- Tampa, FL6 studies
- Cincinnati, OH6 studies
- Madison, WI6 studies
- Ann Arbor, MI6 studies
- Lexington, KY5 studies
- Mountain View, CA5 studies
- Omaha, NE5 studies
- Arlington, VA5 studies
- Queens, NY5 studies
- Charlottesville, VA5 studies
By state
- Alabama9 studies
- Arizona13 studies
- California40 studies
- Colorado14 studies
- Connecticut5 studies
- District of Columbia9 studies
- Florida30 studies
- Georgia12 studies
- Illinois16 studies
- Indiana4 studies
- Iowa4 studies
- Kansas3 studies
- Kentucky5 studies
- Maryland16 studies
- Massachusetts29 studies
- Michigan11 studies
- Minnesota19 studies
- Missouri12 studies
- Nebraska5 studies
- New Jersey8 studies
- New York33 studies
- North Carolina26 studies
- Ohio23 studies
- Oklahoma4 studies
- Pennsylvania21 studies
- Rhode Island3 studies
- South Carolina3 studies
- Tennessee10 studies
- Texas33 studies
- Utah11 studies
- Virginia10 studies
- Washington9 studies
- Wisconsin8 studies
Recently updated studies
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06991101Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT03970447GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07301268GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
RecruitingPhase 1
Ages 21 to 70 · All sexes · Updated Sep 30, 2026 · NCT06815432The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05902169Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05303467Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 28, 2026 · NCT07416188Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07145112A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07195591MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Sep 23, 2026 · NCT06389591OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
RecruitingPhase 2
Ages 18 to 90 · All sexes · Updated Sep 23, 2026 · NCT06558214Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 22, 2026 · NCT06814496A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05765812Anti-GD2 ADC M3554 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06641908VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
RecruitingPhase 2
Ages 18 to 98 · All sexes · Updated Sep 21, 2026 · NCT07831369REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
Recruiting
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07831772Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT04977375ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07089641A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 14, 2026 · NCT05698524From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.